YOLFTbeta
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

AVIR · NASDAQ · Healthcare / Biotechnology

4.30USD+0.09 (+2.14%)

Price History

Full chart

Market Stats

Previous Close4.21
Open4.25
Day Range4.10 – 4.36
52-Week Range2.78 – 6.45
Volume302.65K
Market Cap414.66M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.03
Dividend Yield0.00%
Beta0.28
50-Day Avg5.16
200-Day Avg4.76

About

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jean-Pierre Sommadossi Ph.D.
  • Employees55
  • Headquarters225 Franklin Street, Boston, MA, United States, 02110, USA
  • Websitehttps://ateapharma.com

Leadership

  • Dr. Jean-Pierre Sommadossi Ph.D.Founder, Chairman, CEO & President · b. 1956
  • Ms. Andrea J. Corcoran J.D.CFO, Executive VP of Legal & Secretary · b. 1962
  • Mr. John F. VavrickaChief Commercial Officer · b. 1963
  • Dr. Janet M. J. Hammond M.D., Ph.D.Chief Development Officer · b. 1960
  • Dr. Maria Arantxa Horga M.D.Chief Medical Officer · b. 1968
  • Mr. Wayne Foster CPAExecutive VP of Finance & Chief Accounting Officer · b. 1969
  • Ms. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate Communications
  • Mr. Adel Moussa Ph.D.Executive Vice President of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage Development
  • Mr. Keith PietropaoloExecutive VP of Clinical Sciences & Project Management

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0048.63M351.37M192.18M000
Growth (%)---+622.49%-45.31%-100.00%--
Cost of Revenue17.00K17.00K38.02M29.00K260.00K70.09M83.37M416.00K
Gross Profit-17.00K-17.00K10.61M351.37M-260.00K-70.09M-83.37M-416.00K
Gross Margin--21.82%100.00%-0.14%---
Operating Expense9.46M14.59M21.64M212.99M130.39M94.07M109.58M180.47M
Operating Income-9.48M-14.61M-11.03M138.38M-130.65M-164.16M-192.95M-180.89M
Operating Margin---22.68%39.38%-67.98%---
EBITDA-9.46M-14.59M-11.01M138.41M-130.39M-119.59M-131.80M-164.09M
EBITDA Margin---22.64%39.39%-67.85%---
Net Income-9.06M-13.46M-10.95M121.19M-115.91M-135.96M-168.38M-158.35M
Net Income Margin---22.51%34.49%-60.31%---
R&D6.67M10.17M38.02M167.21M81.94M132.84M145.40M148.02M
R&D as % of Total Revenue--78.18%47.59%42.64%---
Interest Expense0083.00K242.00K11.15M---
Interest Expense % of Total Revenue--0.17%0.07%5.80%---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets34.86M22.07M863.63M772.89M666.71M594.97M464.67M315.22M
Total Liabilities71.02M71.64M315.83M62.81M26.14M39.78M25.80M39.78M
Total Equity-36.16M-49.57M547.80M710.08M640.57M555.19M438.87M275.43M
Cash34.49M21.66M850.12M764.38M646.71M143.82M64.70M95.71M
Total Debt---197.00K3.12M2.40M1.64M843.00K
Net Debt-34.49M-21.66M-850.12M-764.18M-643.59M-141.42M-63.05M-94.87M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.91M-12.81M296.73M-87.00M-120.98M-85.39M-135.50M-132.03M
Investing Cash Flow-12.00K-2.00K-26.00K-4.00K-455.41M40.30M56.10M188.79M
Financing Cash Flow27.48M-15.00K531.75M1.47M370.00K257.00K267.00K-25.75M
Capital Expenditure12.00K2.00K26.00K4.00K1.94M000
Free Cash Flow-7.92M-12.82M296.71M-87.01M-122.92M-85.39M-135.50M-132.03M
FCF to OCF100.15%100.02%99.99%100.00%101.61%100.00%100.00%100.00%

Earnings

Report DateJun 19, 2020Sep 2, 2020Dec 10, 2020Mar 30, 2021May 13, 2021Aug 12, 2021Nov 11, 2021Feb 28, 2022May 10, 2022Aug 8, 2022Nov 7, 2022Feb 28, 2023May 8, 2023Aug 8, 2023Nov 8, 2023Feb 28, 2024May 14, 2024Aug 7, 2024Nov 7, 2024Feb 26, 2025May 12, 2025Aug 7, 2025Nov 12, 2025Mar 5, 2026May 13, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate0.00-0.16-1.810.16-0.050.01-0.050.52-0.58-0.49-0.44-0.45-0.48-0.47-0.46-0.50-0.61-0.77-0.43-0.29-0.41-0.46-0.41-0.48-0.56-0.56-0.50
EPS Actual-0.03-0.16-1.740.960.340.02-0.341.32-0.51-0.38-0.10-0.41-0.43-0.34-0.40-0.47-0.75-0.48-0.37-0.40-0.40-0.44-0.53-0.57-0.57-0.41-
Surprise-0.00%3.87%500.00%780.00%100.00%-580.00%153.85%12.07%22.45%77.27%8.89%10.42%27.66%13.04%6.00%-22.95%37.66%13.95%-38.12%2.44%4.35%-29.27%-18.75%-3.39%26.79%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap414.66M
Enterprise Value204.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.55
Price / Book2.08
EPS-2.03
Book Value2.55
Revenue (TTM)192.18M
Gross Profit (TTM)-155.12M
EBITDA-182.86M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-58.14%
Return on Assets-36.72%
Shares Outstanding80.20M
Shares Float60.34M
Beta0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 9.42
  • Strong Buy
    1
  • Hold
    1
  • Sell
    1

Ownership Breakdown

Institutions
79.14%
Insiders
13.37%
Retail / Other
7.49%

Top Institutional Holders

  • FMR Inc
    11.95M14.90%
  • BlackRock Inc
    8.44M10.52%
  • BML Capital Management LLC
    6.95M8.67%
  • TANG CAPITAL MANAGEMENT LLC
    4.81M6.00%
  • Vanguard Capital Management, LLC
    3.25M4.05%
  • Bain Capital Life Sciences Investors, LLC
    2.36M2.94%
  • Geode Capital Management, LLC
    1.75M2.18%
  • State Street Corp
    1.69M2.11%
  • Acadian Asset Management LLC
    1.58M1.97%
  • Two Sigma Investments LLC
    1.51M1.88%
  • Dimensional Fund Advisors, Inc.
    1.30M1.62%
  • Rosalind Advisors, Inc.
    1.17M1.46%
  • Renaissance Technologies Corp
    1.17M1.45%
  • JPMorgan Chase & Co
    940.16K1.17%

Top Fund Holders

  • Fidelity Growth Company Fund
    3.10M3.86%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.03M2.53%
  • iShares Russell 2000 ETF
    1.81M2.25%
  • Fidelity Growth Company K6
    1.22M1.52%
  • Fidelity Small Cap Index
    769.17K0.96%
  • Fidelity Series Growth Company
    733.90K0.92%